The medical black technology system of the top student

As clinical trial data of PD-1/TIGIT inhibitors are released online.

This news is like dropping a bomb on the Internet, especially on the cusp of such a storm, the impact will undoubtedly be huge.

After all, Moco had just issued a statement, implying that Lu Liang did not dare to publish the clinical data.

As a result, it was only a few hours before someone dumped the data on his face.

In particular, this data was jointly released by two authorities, the Pharmaceutical University and the Institute of Materia Medica, confirming the authenticity of the data.

This time Moco Company was speechless.

At the same time, Moco Company, the meeting continued.

Lu Liang suddenly announced clinical data, which caught Zheng Yi off guard.

You know, she was making bold words here just now, but the result turned around so quickly.

Dai Yang narrowed his eyes slightly, looked at Zheng Yi and asked, "Dr. Zheng, how do you explain this time?"

Not only Dai Yang, but also several other shareholders present looked like they were launching an attack to investigate.

Although she was a little embarrassed, Zheng Yi calmed down and regained her usual calmness.

Zheng Yi took a deep breath and said: "Don't worry, Chairman, we have to look at the data before making a conclusion."

"Well, Chairman, if his medicine is really better than mine, I will resign and get out now."

Hearing Zheng Yi's harsh words, everyone was shocked. Even Dai Yang looked surprised.

They all don't understand why Zheng Yi can still be so confident at this point?

In fact, this is not because Zheng Yi is confident. On the contrary, Zheng Yi actually has no confidence at this moment.

But she knew that her current situation was one from which she could not retreat.

If Lu Liang's medicine is really better than his, even if she doesn't say these harsh words now, she will be slowly squeezed out of the company because of this matter later.

Therefore, the only thing she can do now is to be stubborn.

However, Zheng Yi has already thought of a way out for herself.

Sugalimab can have a therapeutic effect on three types of lung cancer patients with EGFR gene mutations, ALK mutations, and ROS gene fusions.

As long as the therapeutic effect of sugalimab on a certain type of lung cancer patients exceeds that of Lu Liang's drug, even if it is just a little more, even if it is only 1%.

Zheng Yi could make a big fuss out of this and insisted that the therapeutic effect of sugemalimab on lung cancer patients was better than Lu Liang's drug in some aspects.

Block the mouths of Dai Yang and others before talking.

After all, she really didn't want to just pack up her things and leave the company.

Unless Lu Liang's drug can completely crush sugemalimab in terms of therapeutic effect, every data is better than sugemalimab.

But this possibility is almost slim.

Thinking of this, Zheng Yi relaxed a little.

Sure enough, as Zheng Yi said these words, Dai Yang and several shareholders present shut up. Zheng Yi had already said this, so what else did they have to say.

Then, Zheng Yi looked at the secretary and asked, "Let's first compare the ORR of ROS gene fusion lung cancer patients."

"In our clinical trials of sugalimab, the ORR for patients with ROS gene fusion lung cancer was the lowest, only 78%. What is the ORR of their drug?"

The secretary spoke cautiously: "Their drug has an ORR of 82% for lung cancer patients with ROS fusion genes."

As the secretary's words came out, the entire conference room suddenly became quiet, and several shareholders present looked at Zheng Yi with strange expressions.

Zheng Yi was silent for a moment, but still pretended to be calm and laughed dryly: "This undergraduate student from the Pharmaceutical University is more capable than I thought."

Immediately, Zheng Yi explained: "However, there is no need to panic. After all, the proportion of lung cancer patients with ROS gene fusion among all lung cancer patients is not high, only 2.6%."

"Their drug has an ORR of 86% for lung cancer patients with ROS fusion genes, indicating that their drugs may mainly target lung cancer patients with ROS gene fusions."

"Our sugemalimab is different."

Zheng Yi seemed to calmly explain a lot to all the shareholders present and Dai Yang.

But in fact, Zheng Yi started to panic. She didn't understand how Lu Liang managed to increase the ORR of ROS gene fusion lung cancer patients to 86%.

This is already higher than the ORR of those targeted drugs that specifically target ROS.

However, Zheng Yi still comforted herself silently in her heart.

She still has a chance now. After all, sugemalimab has the worst therapeutic effect on ROS lung cancer patients. As long as she does not lose in EGFR mutations and ALK mutations, it will be fine.

Thinking of this, Zheng Yi looked at her secretary and asked, "Then the ALK mutation?"

The ORR of sugalimab in lung cancer patients with ALK gene mutations is as high as 83%, which Zheng Yi has always been quite satisfied with.

The secretary replied weakly: "From the data, their drug has an ORR of 90% for lung cancer patients with ALK gene mutations."

As soon as these words came out, the entire conference room fell silent again, and everyone looked at Zheng Yi.

Zheng Yi was silent for a while, but she could only continue to speak harshly: "Ahem, it's a bit unexpected."

"However, this does not matter. Lung cancer patients with ALK gene mutations only account for 13.9% of all lung cancer patients, so it does not have a great impact on us."

Zheng Yi continued: "Our main customer group for sugalimab is still those lung cancer patients with EGFR gene mutations."

"Lung cancer patients with EGFR gene mutations account for more than 50% of all lung cancer patients. That is to say, for every two lung cancer patients, one lung cancer patient has an EGFR gene mutation."

“And our sugemalimab can achieve an ORR of 92% in lung cancer patients with EGFR gene mutations.”

When Zheng Yi talked about this, her expression became confident again.

After all, the ORR for EGFR gene mutations can reach 92%, which has always been her confidence.

Zheng Yi didn't believe it. At this point, Lu Liang's medicine could do better than hers.

Thinking of this, Zheng Yi naturally looked at his secretary.

"But. But" after noticing Zheng Yi's gaze, the secretary suddenly became hesitant.

This made Zheng Yi wonder: "But what."

The secretary gritted his teeth and said, "Their drug has an ORR of 97% for lung cancer patients with EGFR gene mutations!"

"impossible!"

Zheng Yi looked horrified, and she subconsciously blurted out.

97%, what a joke.

"Did you see it wrong?" Zheng Yi's voice trembled.

"Dr. Zheng, you'd better read it yourself." The secretary gritted his teeth and handed the printed data into Zheng Yi's hands.

Zheng Yi flipped through it quickly, but the data on it almost made her feel suffocated.

Clinical trial results of PD-1/TIGIT inhibitors.

EGFR gene mutation: 97%

ALK gene mutation: 90%

ROS fusion gene: 82%

KRAS gene mutation: 86%

PD-1/TIGIT inhibitors cover almost all types of lung cancer.

This is no longer an effect that surpasses sugemalimab. Compared with PD-1/TIGIT inhibitors, sugemalimab was simply crushed into slag.

When Zheng Yi saw this data, his eyes went dark, and then he lost consciousness.